Drug Trial Radar · NCT01472185
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Oct 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
465
Actual
Start
Nov 2011
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones \[TZDs\] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.
Conditions
- Type 2 Diabetes Mellitus
Interventions
RanolazineDrug
Ranolazine tablets administered orally twice daily.
PlaceboDrug
Placebo to match ranolazine administered orally twice daily.
DietBehavioral
Participants are instructed to continue the diet regimen prescribed by their physician.
ExerciseBehavioral
Participants are instructed to continue the exercise regimen prescribed by their physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Time frame: Baseline; Week 24
Locations
159 sites in 10 countries. Site status is shown where the registry gives one.
Thunderbird Internal Medicine/Clinical Research Advantage
Glendale, Arizona
Central Phoenix Medical Clinic
Phoenix, Arizona
Desert Sun Clinical Research, LLC
Tucson, Arizona
Eclipse Clinical Research
Tucson, Arizona
North Central Arkansas Medical Associates
Mountain Home, Arkansas
Paul W. Davis, MD, Private Practice
Pine Bluff, Arkansas
Southland Clinical Research Center, Inc.
Fountain Valley, California
Global Research Management
Glendale, California
National Research Institute
Los Angeles, California
Spectrum Clinical Research Institute, Inc
Moreno Valley, California
Sacramento Heart and Vascular Medical Associates
Sacramento, California
Clearview Medical Research LLC
Santa Clarita, California
Infosphere Clinical Research
West Hills, California
Boca Raton Clinical Research Associates, Inc
Boca Raton, Florida
PAB Clinical Research
Brandon, Florida
Florida Research Network, LLC
Gainesville, Florida
A G A Clinical Trials
Hialeah, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Baptist Diabetes Associates
Miami, Florida
NextPhase Clinical Trials, Inc.
Miami Beach, Florida
Precision Research Organization
Miami Lakes, Florida
Suncoast Clinical Research
New Port Richey, Florida
Florida Institute for Clinical Research LLC
Orlando, Florida
Regenerate Clinical Trials
South Miami, Florida
Synergy Therapeutic Partners
Atlanta, Georgia
CTL Research
Eagle, Idaho
Cedar-Crosse Research Center
Chicago, Illinois
LaPorte County Institute for Clinical Research
Michigan City, Indiana
Clinical Trials Management, LLC
Metairie, Louisiana
MD Medical Research
Oxon Hill, Maryland
IRC Clinics, Inc
Towson, Maryland
Associated Internal Medicine Specialists, P.C.
Battle Creek, Michigan
Albuquerque Clinical Trials
Albuquerque, New Mexico
University of New Mexico Clinical and Translational Science Center
Albuquerque, New Mexico
Clinical Research Solution
New York, New York
PMG Research of Charlotte
Charlotte, North Carolina
PharmQuest
Greensboro, North Carolina
PMG Research of Salisbury
Salisbury, North Carolina
Clinical Inquest Center, Ltd.
Beavercreek, Ohio
Infinity Research Group, LLC
Oklahoma City, Oklahoma
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.